Table 3.
Subsequent therapy costs
| Avelumab + BSC | BSC alone | |
|---|---|---|
| Total subsequent treatment cost on progression | €10,239.40 | €35,848.88 |
BSC best supportive care
Source: Z-index and JAVELIN Bladder 100 study
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.